Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates using its proprietary POZ (poly(2-oxazoline)) polymer platform, a synthetic water-soluble polymer designed to modify and enhance existing and novel drugs across small molecules, RNA-based therapeutics, and antibody-drug conjugates. POZ offers distinct advantages over competing technologies such as PEG, including simpler and safer synthesis, lack of immunogenicity, higher drug loading capacity, complete renal clearance without tissue accumulation, and multiple sites for simultaneous drug and targeting molecule attachment. The company's lead program, SER 252 (POZ-apomorphine), targets advanced Parkinson's disease by enabling continuous dopaminergic stimulation via subcutaneous injection, while a secondary pipeline includes POZ-lipid alternatives for vaccines and other applications pursued through partnerships; Serina generates revenue through out-licensing, milestone payments, and royalties on licensed technology.